No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BIO Bio-Rad Laboratories
- 279.910
- -2.060-0.73%
Close May 7 16:00 ET
- 279.110
- -0.800-0.29%
Post 19:56 ET
7.98BMarket Cap-12828P/E (TTM)
283.010High278.880Low201.72KVolume281.470Open281.970Pre Close56.59MTurnover1.01%Turnover RatioLossP/E (Static)28.52MShares431.79052wk High0.91P/B5.59BFloat Cap261.59052wk Low--Dividend TTM19.96MShs Float832.700Historical High--Div YieldTTM1.47%Amplitude9.438Historical Low280.534Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Research Alert: CFRA Retains Hold Opinion On Shares Of Bio-rad Laboratories, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We cut our target to $290 from $360, 24.
Bio-Rad Laboratories Inc (BIO) Q1 2024 Earnings: Mixed Results Amid Market Challenges
Bio-Rad Laboratories Q1 Non-GAAP Earnings, Revenue Decline
Bio-Rad Laboratories (BIO) reported Q1 non-GAAP net income Tuesday of $2.29 per diluted share, down from $3.34 a year earlier. Four analysts polled by Capital IQ expected $2.14 per share. Revenue for
Express News | Bio Rad Laboratories Inc FY2024 Shr View $10.61, Rev View $2.69 Bln -- Lseg Ibes Data
Express News | Bio Rad Laboratories Inc: Maintaining Its Financial Outlook for Full Year 2024
Express News | Bio-Rad Maintains Its FY24 Financial Outlook
Comments
$Sunshine Biopharma(SBFM.US$ SHORTS time to say hello to my little friend $Bio-Rad Laboratories(BIO.US$
Despite a superior revenue outlook, the company isn't trading at a higher P/S due to potential risks like not meeting analysts' revenue projections in tough industry conditions. Investors anticipate future revenue volatility.
Bio-Rad's unstable profits and stale growth over the past three years are worrying. Despite a rise in stocks, long-term performance lacks strength. If fundamentals signal sustainable growth, the current sell-off could be a chance.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Live Nation Entertainment(LYV.US$ - up 9.3%
2. $BILL Holdings(BILL.US$ - up 8.7%
3. $Coinbase(COIN.US$ - up 6.5%
4. $DraftKings(DKNG.US$ - up 6.2%
5. $Apellis Pharmaceuticals(APLS.US$ - up 5.3%
6. $Reinsurance Group of America(RGA.US$ - up 3.9%
7. $Equinor(EQNR.US$ - up 3.7...
Gap Ups
1. $Live Nation Entertainment(LYV.US$ - up 9.3%
2. $BILL Holdings(BILL.US$ - up 8.7%
3. $Coinbase(COIN.US$ - up 6.5%
4. $DraftKings(DKNG.US$ - up 6.2%
5. $Apellis Pharmaceuticals(APLS.US$ - up 5.3%
6. $Reinsurance Group of America(RGA.US$ - up 3.9%
7. $Equinor(EQNR.US$ - up 3.7...
+16
16
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg